USA flag logo/image

An Official Website of the United States Government

SBIR Phase I: Hyperosmotic nanoemulsions as therapeutics for the prevention and…

Award Information

Agency:
National Science Foundation
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
1248852
Solicitation Year:
2012
Solicitation Topic Code:
BC
Solicitation Number:
Small Business Information
Medtric Biotech, LLC
3000 Kent Avenue Suite D1-103 West Lafayette, IN 47906-1075
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2013
Title: SBIR Phase I: Hyperosmotic nanoemulsions as therapeutics for the prevention and treatment of infected wounds
Agency: NSF
Contract: 1248852
Award Amount: $150,000.00
 

Abstract:

This Small Business Innovation Research (SBIR) Phase I project seeks to develop novel hyperosmotic nanoemulsions for the prevention and treatment of infected wounds. Wound infections, whether acute or chronic, affects millions of Americans and have significant monetary and physiologic impacts on patient quality of life. Current therapies that rely on antibiotics are becoming limited due to the frequency of antibiotic drug resistance. For example, the CDC estimates that drug resistance has increased 36% in the last twenty years. To reduce the reliance on broad spectrum antibiotics, this research aims to develop a new class (non-antibiotic) of topical therapeutics known as hyperosmotic nanoemulsions. The intellectual merit of the proposed technology is the novel mechanism of bactericidal action (for infection prevention/treatment) coupled to the concomitant acceleration in wound healing. This proposal is intended to define the optimal treatment dosage necessary to move the technology into human clinical testing. The broader impact/commercial potential of this project is the applicability of hyperosmotic nanoemulsions to become a standard first option in wound management protocol. Currently, market products either mitigate the infection or reduce healing times. However, hyperosmotic nanoemulsions are intended to treat both the underlying infection and actively promote the stages of wound healing. This dual-fold action is poised to disrupt the market of advanced wound dressings, which is estimated to be $1.2B and growing 10% annually. Other markets that may be addressed with the proposed technology include topical acne, antiviral and antifungal segments. The proposed platform technology may ultimately prove to be an alternative or supplement to traditional drugs and reshape both veterinary and human clinical practice.

Principal Investigator:

Sean Connell
8328654955
connell@medtricbiotech.com

Business Contact:

Sean Connell
8328654955
connell@medtricbiotech.com
Small Business Information at Submission:

Medtric Biotech, LLC
3000 Kent Avenue Suite D1-103 West Lafayette, IN 47906-1075

EIN/Tax ID: 274550404
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No